Fluacizine
From Wikipedia, the free encyclopedia
 |
|
|
Fluacizine
|
|
| Systematic (IUPAC) name | |
| 3-diethylamino-1-[2-(trifluoromethyl) phenothiazin-10-yl]-propan-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C20H21F3N2OS |
| Mol. mass | 394.455 g/mol |
| SMILES | & |
| Synonyms | Flouracizine, Phtorazisin, ftoracizin, 10-(3-(Diethylamino)propionyl) -2-(trifluoromethyl)phenothiazine, 2-(Trifluoromethyl)-10- (N,N-diethyl-beta-alanyl)phenothiazine |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, intramuscular |
Fluacizine (INN) is an antidepressant with sedative properties derived from phenothiazine.
Fluacizine possesses strong central and peripheral anticholinergic activity.
Contents |
[edit] Uses
[edit] Approved
Fluacizine is indicated in bipolar depression, the emotional problems accompanying schizophrenia, anxiety accompanying depression, and for the depressive and extrapyramidal symptoms resulting from neuroleptic therapy. It is not effective for atypical depression or late-onset depression (once known as involutional melancholia).
[edit] Side effects
Side effects of fluacizine include feeling of weakness, nausea, and dry mouth.
[edit] Contraindications
Fluacizine is contraindicated in patients with liver or kidney impairment, enlarged prostate, peptic ulcer or who have taken MAOIs less than 14 days before starting therapy.
